---
title: 'This 1 Gene Extends Lifespan by 14%'
source: 'https://youtube.com/watch?v=_TpT3eXpyIE'
video_id: '_TpT3eXpyIE'
date: 2026-11-03
duration_sec: 867
channel: 'Modern Healthspan'
---

# This 1 Gene Extends Lifespan by 14%

> Source: [This 1 Gene Extends Lifespan by 14%](https://youtube.com/watch?v=_TpT3eXpyIE)

## Summary

This video analyzes a groundbreaking study from Dr. George Church's laboratory at Harvard Medical School, published in Nature Aging, which reports a 14% increase in median lifespan in aged female mice using a single gene, SRSF1. The study highlights a novel approach to cellular rejuvenation that targets RNA splicing rather than the traditional Yamanaka factors, potentially offering a safer alternative. The video also discusses the implications, limitations, and the race in private biotechnology to develop single-gene rejuvenation therapies.

### Key Points

- **Study Overview** [00:07] — A study from Dr. George Church's lab at Harvard Medical School and the Weiss Institute, published in Nature Aging, reported a 14% increase in median lifespan in aged female mice using a single gene, SRSF1.
- **Yamanaka Factors vs. SRSF1** [00:37] — Traditional rejuvenation uses Yamanaka factors (OCT4, SOX2, KLF4, c-MYC), which can erase cell identity and cause tumors. SRSF1 targets RNA splicing instead of forcing cells back to an embryonic state, potentially avoiding these risks.
- **SRSF1 as Proto-Oncogene** [01:10] — SRSF1 is a well-documented proto-oncogene; elevated activity helps certain cancer cells evade programmed cell death. The challenge is harnessing its repair signals without triggering uncontrolled growth.
- **Research Methodology** [01:38] — The team built a 292-gene transcriptomic clock trained on 133 human skin fibroblast lines (donors aged 1-96) to identify master regulators of aging. They overexpressed 89 candidate genes in older donor cells, and SRSF1 emerged as the most consistent hit.
- **Mechanism of Splicing** [02:32] — RNA splicing is like editing a rehearsal draft; as cells age, splicing precision declines, leading to flawed proteins. SRSF1 acts as an essential editor in this process.
- **In Vitro Results** [03:31] — Restoring SRSF1 in fibroblasts from older donors shifted gene expression towards a younger profile (e.g., 16 years in a 79-year-old donor, though with a margin of error of ~9.5 years). DNA methylation clocks showed mixed results, and senescence markers were split.
- **Cell Identity Preserved** [05:13] — Unlike Yamanaka factors, SRSF1 treatment maintained cell identity; fibroblasts kept their shape and specialized programs, with pluripotency markers (OCT4, SOX2, NANOG) remaining silent.
- **In Vivo Mouse Study** [05:30] — An AAV8 vector with an inducible SRSF1 gene was delivered to 19 female mice (10 treated, 9 control). Median survival increased from 778 days (control) to 886 days (treated), a 14% increase.
- **Caveats of Mouse Study** [07:08] — The control group's median survival (778 days) was below standard benchmarks (850-900 days), so the treated group's 886 days brought them into normal range. The study used only female mice and a small cohort.
- **Functional Health and Frailty** [07:51] — A composite frailty score accumulated 44% more slowly in treated mice, and onset of physical frailty was delayed by ~123 days. Individual performance metrics were not statistically significant after corrections.
- **Dosage is Decisive** [08:32] — High continuous expression of SRSF1 failed to provide benefits in wound healing and muscle regeneration models; only moderate pulsed induction supported survival.
- **Shift Biosciences Comparison** [09:03] — Shift Biosciences published a preprint on their candidate SB0000, which rolled back epigenetic clocks in cultured cells, but they kept the gene identity confidential. They used SRSF1 as a benchmark, but their data lacks animal survival data.
- **Commercial and Academic Dynamics** [10:34] — Dr. Church's lab published openly but also filed patents on SRSF1 and co-founded a company (Regular Bio) to develop it commercially.
- **Delivery Advantages** [11:05] — SRSF1's coding sequence is ~747 base pairs, fitting easily into a single AAV vector (cargo limit ~4.7 kb), unlike Yamanaka factors which push the limit. However, systemic AAV delivery has toxicity risks.
- **Human Trial Context** [12:05] — Life Biosciences reported preliminary Phase 1 safety data for an inducible Yamanaka factor therapy for glaucoma, which was well tolerated in three patients. However, this is in the immune-privileged eye, not systemic.
- **Future Outlook** [13:09] — No human trials exist for SRSF1. Due to its proto-oncogene activity, extensive toxicology studies are needed. Future therapies will likely target localized tissues rather than systemic longevity.

### Conclusion

The discovery of SRSF1 as a single-gene rejuvenation factor represents a significant step forward, offering a potential alternative to Yamanaka factors with a more targeted approach. However, significant safety concerns, particularly its oncogenic potential, and the need for extensive further research mean that human applications remain a distant prospect.

## Transcript

lifespan without the dangerous tumor risks of yamanaka factors? A study published in Nature Aging from Dr. George Church's laboratory at Harvard Medical School and the Weiss Institute reported a 14% increase in
median lifespan in aged female mice using a single gene, an RNA splicing factor called SRSF1. rejuvenation has relied on four transcription factors known as the
transcription factors known as the Yamanaka cocktail, O 4, SOCK 2, KF4 and CMIC. While these factors can roll back cellular age, continuous expression erases cell identity and tissues can collapse into lethal embryionic tumors
called terteratomomas. SRSF-1 approaches cellular aging from a different angle. Instead of forcing cells backwards towards an embryionic state, it targets how cells edit their RNA messages. However, SRSF-1 is also a
wellocumented protoona gene. In oncology research, elevated SRSF-1 activity helps certain lung, breast, and colon cancer cells evade programmed cell
death. The central scientific challenge is whether researchers can harness its cellular repair signals without triggering uncontrolled cell growth. The paper led by Alex Pleser alongside computational geneticist
Antonio del Soul and George Church began with a research for master regulators of aging. The team built a 292 gene transcrytoic clock trained on 133 human
transcrytoic clock trained on 133 human skin fibroblast lines spanning donors from age 1 to 96. This model tracked age associated shifts across cellular pathways including protein synthesis,
stress responses. Using this model as a functional filter, the researchers overexpressed 89 candidate genes in cultured skin cells candidate genes in cultured skin cells from older human donors aged 55, 65, and
79. SRSF-1 emerged as the most consistent hit. Its baseline expression naturally declines as cells age and restoring its activity shifted cellular gene expression patterns back towards a
younger profile. To understand why splicing factors affect aging, think of your DNA as a library of scripts and RNA is the library of scripts and RNA is the rehearsal draft. When a cell activates a
gene, it first transcribes a long precursor RNA message. A molecular editing machine called the splicosome cuts out non-coding segments and stitches together coding pieces. By rearranging these pieces, a single gene
can produce several distinct protein variations suited for different cellular variations suited for different cellular needs. As cells age, that editing precision begins to slip. Splyomes make mistakes, cutting at the wrong spots and
assembling flawed protein variants that clutter cellular waste disposal and strain cellular health. SRSF-1 acts as an essential editor in that splicing process. When the Harvard team restored SRSF-1 in cultured
fibroblast from older human donors, several measurable changes occurred. First, the custom gene expression clock shifted towards a younger baseline. In cells from 79y old donor, the transcripttoic model showed a shift of
16 years. That clock has an inherent margin of error of roughly 9 and a half years. So, this is a modeled metric rather than 16 calendar year returned. DNA methylation clock showed mixed results. Methylation age scores dropped
results. Methylation age scores dropped in cells from 55 and 79 year old donors, but actually increased slightly in cells from the 68-y old donor. Short pulses of expression did not leave a permanent epigenetic mark once the genes were
turned off. Second, cellular scinessence markers produced a split verdict. staining for scinessence associated beta galactoidase dropped significantly after introducing
SRSF-1 messenger RNA. The classical tumor suppressor and scinessence arrest protein P16 showed no significant change. The treated cells were still actively dividing fibrobars in culture, not terminally arrest scinsesscent cells
pulled back from the brink. Third, while the expression of endogenous DNA repair pathways increased, the physical reduction in cellular DNA damage markers fell short of statistical significance.
The clearest advantage over Yamanaka factors appeared in cell identity. Throughout the experiment, the human fibroblasts maintained their classic elongated shape and kept their specialized structural programs active.
Pluropotency markers like oct 4, sock 2 and nanog stayed completely silent. The cells improved aspects of their function without taking a single step towards becoming embryionic stem cells. Cell culture screens show what is
biologically possible in a plastic dish. They do not prove that an intervention helps complex living animals survive longer. To test SRSF-1 in vivo, the researchers engineered an adinoass associated virus, specifically a liver
tropic Aava vector carrying the mouse version of SRSF-1 gene. They placed this gene under a teton inducible switch. This meant the vectors remained dormant
until the animals received the antibiotic doxycycline in their drinking water. The researchers delivered the vector systemically to female mice at vector systemically to female mice at 561 days of age, roughly 18 months old,
or about 55 in human terms, and activated the gene expression at 606 activated the gene expression at 606 days, which is closer to 60 for humans. The cohort was small, 19 female mice in total. 10 mice received the inducible
SRSF-1 vector and nine control mice received an identical AAV8 vector delivering green fluorescent protein. Both groups received doxycyc.
Median survival in the control group was 778 days. In the SRSF-1 treated group, 778 days. In the SRSF-1 treated group, median survival reached 886 days. That is an increase of 108 days or roughly 14%.
But several caveats require context. First, the study examined female mice only. Second, the control group's median survival of 778 days sat noticeably
below standard published benchmarks for female C-57 BL6 mice, which typically range between 850 and 900 days under optimal husbandry conditions. The control mice lived roughly 2 to four
months less than expected, meaning the treated group's 886 day median brought them into normal baseline range rather than pushing past elite lifespan limits.
Third, 19 animals in a single late life experiment represent an exploratory Functional health showed a similar nuance. A modeled composite frailty score accumulated 44% more slowly in the treated group and the onset of sustained
physical frailty was delayed by approximately 123 days in the subset of approximately 123 days in the subset of mice that developed it. When researchers analyzed individual physical performance metrics such as grip strength, coke
condition, and motor coordination, none of them remained statistically significant after correcting for multiple comparisons in the liver. One intervention optimized DNA methylation clocks registered a halfyear reduction
in biological age. Chronological and pan tissue clocks showed no significant difference and the study did not measure hisytological reversal of liver hisytological reversal of liver fibrosis. Crucially, dosage proved
decisive. When the authors tested high continuous expression of SRSF1 in separate wound healing and and muscle regeneration models, the treatment failed to provide a benefit. The only setting that supported survival was
moderate pulseed induction. This publication also brings clarity to a parallel race in private biotechnology. In June 2025, Cambridgebased Shift Biosciences published a preprint date detailing their lead candidate
designated SB0000. Using machine learning to search for a single gene rejuvenation factors, Shift reported that SB0000 rolled back multiple epigenetic clocks in cultured human fibroblasts over six
weeks of expression. On the principal component Horovvath On the principal component Horovvath 2013 clock they observed an epigenetic roll back of 7.4 years alongside a modest reduction of 0.132 on the dunin
pace pace of aging metric because both groups used machine learning to screen for single gene rejuvenation targets. I wondered if Shift and Harvard had converged on the same factor. While Shift Bioscience kept the exact genetic
identity of SP0000 confidential to protect their internal pipeline and raise venture funding, they explicitly used SRSF-1 as a primary benchmark in the preprint comparing SP00 directly against it to demonstrate superior
rejuvenation. The differences between their data sets are substantial. Schiff demonstrated clock reductions in cultured cells, but their preprint contains zero living animal survival data. The Church
Laboratory disclosed the sequence of SRSF-1 detailed its molecular pathways and provided living animal survival curves. This dynamic extends beyond academic altruism versus commercial secrecy.
While Dr. Church and his co- co-authors published their targets openly. They also filed patent claims on SRSF-1 and co-founded a biotechnology company regular bio to develop it commercially. Where does single gene rejuvenation
stand on the path towards human clinical medicine? On the delivery side, SRSF-1 offers an engineering advantage. The clinical standard for human gene therapy clinical standard for human gene therapy is adinoassociated virus or AAV. AAV has
a strict physical cargo ceiling of roughly 4.7 kilobases. Squeezing three large Yamanaka factors alongside their regulatory elements pushes that vector regulatory elements pushes that vector to its physical limit. SRSF-1's protein
coding sequence is roughly 747 base pairs. That compact footprint fits easily into a single AAV vector, leaving plenty of space for inducible molecular switches. Vector size alone does not resolve safety. Systemic AAV delivery
requires high viral doses that have caused severe liver toxicity in human clinical trials. Furthermore, controlling an inducible gene like SRSF-1 in humans currently depends on drug switches like Teton, which require
long courses of systemic antibiotics like doxycyc. Chronic antibiotic administration carries clear risks of gut microbiome carries clear risks of gut microbiome disruption and mitochondrial stress. We
already have an early benchmark of inducible reprogramming in humans. In inducible reprogramming in humans. In October 2026, Life Biosciences announced preliminary phase 1 safety data for their candidate ER 100, an inducible
AAV2 vector carrying three Yamanaka factors, Oct 4, SOX 2, and KF4 for primary open angle glaucom. In that trial's initial cohort of three
patients, daily oral doxycycline induction for 56 consecutive days was well tolerated with no dose limiting toxicities. That result is an encouraging first step, but its scope is narrow.
Delivering an inducible vector into the immuneprivileged environment of the human eye tells us very little about the safety of infusing viral vectors into the bloodstream or turning on growth factors across systemic organs.
For SRSF-1 specifically, no human clinical trials exist and no regulatory applications have been filed. Because of its known activity as a protoona gene in
human epithelial cancers, any eventual human program will require extensive multi-year toxicology studies in larger animal models to prove that temporary activation does not see microscopic tumors. If single gene splicing
therapies ever reach human trials, they will almost certainly target localized contained tissues rather than systemic longevity. The discovery is of SRSF-1 adds an important chapter to cellular rejuvenation research. Moving forward,
the active challenge is proving whether researchers can stimulate cellular repair through splicing without triggering the encogenic risk linked to SRSF-1. Now I would like to hear from you. When
you look at the future of cellular reprogramming, do you see targeted splicing factors like SRSF-1 as a safer path forward than Yamanaka factors or does their encogenic potential present too high a hurdle for healthy humans?
Share your thoughts in the comments below. Thank you for watching and I wish below. Thank you for watching and I wish you all well.
